In CRC, tumor-infiltrating lymphocytes are composed of anti-tumorigenic CD4+ (Th1 or Th22) and pro-tumorigenic CD4+ (Th17 or Tregs) cells, and the ratio of anti- and pro-tumor T cells is crucial for tumor progression [157]. This evidence concerns the gene CD4 and neoplasm.